Telomir Pharmaceuticals Files 8-K
Ticker: TELO · Form: 8-K · Filed: Oct 22, 2025 · CIK: 1971532
Sentiment: neutral
Topics: 8-K, other-events
TL;DR
Telomir Pharma filed an 8-K for 'Other Events' on Oct 22, 2025. Details TBD.
AI Summary
On October 22, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding the nature of these events, any associated financial figures, or other named parties were provided in the excerpt.
Why It Matters
This filing signals a material event has occurred for Telomir Pharmaceuticals, requiring disclosure to investors. The lack of detail in the provided excerpt necessitates further investigation to understand the implications.
Risk Assessment
Risk Level: medium — The filing indicates a material event has occurred, but the lack of specific details in the provided text creates uncertainty about the nature and impact of these events.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- October 22, 2025 (date) — Date of earliest event reported
FAQ
What specific 'Other Events' are being reported by Telomir Pharmaceuticals, Inc. in this 8-K filing?
The provided excerpt of the 8-K filing does not specify the nature of the 'Other Events'.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is October 22, 2025.
What is the principal executive office address for Telomir Pharmaceuticals, Inc.?
The principal executive offices are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida 33131.
What is the telephone number for Telomir Pharmaceuticals, Inc.?
The registrant's telephone number, including area code, is (786) 396-6723.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 711 words · 3 min read · ~2 pages · Grade level 16.7 · Accepted 2025-10-22 16:01:35
Filing Documents
- form8-k.htm (8-K) — 39KB
- 0001493152-25-018907.txt ( ) — 205KB
- telo-20251022.xsd (EX-101.SCH) — 3KB
- telo-20251022_lab.xml (EX-101.LAB) — 33KB
- telo-20251022_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACEUTICALS, INC. Dated: October 22, 2025 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer